Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 676

Sort by

Sort Order Select

Journal Articles

Simultaneous bone marrow involvement by CLL/SLL and LEF1/cyclin D1-positive metastatic melanoma

Kirill A. Lyapichev, Fatima Z. Jelloul

Blood (2020) 136 (2): 258.

https://doi.org/10.1182/blood.2020006057

Published: 2020

Journal Articles

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

Matthew Lunning, Julie Vose, Loretta Nastoupil, Nathan Fowler, Jan A. Burger, William G. Wierda, Marshall T. Schreeder, Tanya Siddiqi, Christopher R. Flowers, Jonathon B. Cohen, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Susan O’Brien

Blood (2019) 134 (21): 1811–1820.

https://doi.org/10.1182/blood.2019002118

Published: 2019

Includes: Supplemental data

Journal Articles

Combining Gene Expression Profiling and Artificial Intelligence to Diagnose B-Cell Non-Hodgkin Lymphoma

Victor Bobée, PharmD, Fanny Drieux, MD, Vinciane Marchand, Vincent Sater, Liana Veresezan, MD, Jean-Michel Picquenot, MD, Pierre-Julien Viailly, Marie-delphine Lanic, Mathieu Viennot, Elodie Bohers, PhD, Lucie Oberic, MD, Christiane Copie-Bergman, MD PhD, Thierry Jo Molina, MD PhD, Philippe Gaulard, MD PhD, Corinne Haioun, MD PhD, Gilles A. Salles, MD PhD, Herve Tilly, MD PhD, Fabrice Jardin, Philippe Ruminy, PhD

Blood (2019) 134 (Supplement_1): 1476.

https://doi.org/10.1182/blood-2019-122405

Published: 2019

Journal Articles

Efficacy and Safety of Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia

Zhijian Cao, MD, Jun Ma, MD PhD

Blood (2019) 134 (Supplement_1): 5478.

https://doi.org/10.1182/blood-2019-126686

Published: 2019

Journal Articles

Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Combined Analysis of Three Phase III Randomized Controlled Trials

Sriman Swarup, MDMBBS, Donald P. Quick, MD, Anita Sultan, MD, Nicholas D'Cunha, MD, Thura Win Htut, MBBS, MRCP, Pwint Phyu Hlaing, MD, Upama Sharma, Nimesh Adhikari, MD, Ye Aung, Myat Min Han, MD, Yin Mon Myat, MD, Fred Hardwicke, MD, Lukman Tijani, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 5479.

https://doi.org/10.1182/blood-2019-123172

Published: 2019

Journal Articles

Decreased Thrombin Generation Potential in Lymphoma Patients Is Associated with Increased D-Dimer, CRP, Vwf and TNF-α. Interrelationship between Thrombogenesis and Inflammation

Fakiha Siddiqui, Emily Bontekoe, Darko Antic, PhD, Debra Hoppensteadt, PhD, Grigoris Gerotziafas, MD PhD, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 5239.

https://doi.org/10.1182/blood-2019-128440

Published: 2019

Journal Articles

Efficacy of Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Anita Sultan, MD, Bradley J. Grant, JD, Donald P. Quick, MD, Chandler Graf, Sriman Swarup, MDMBBS, Sriman Swarup, MDMBBS, Jonathan Kopel, BS, Thura Win Htut, MBBS, MRCP, Somedeb Ball, MD, Ei Moe Phyu, MD, Myat Min Han, MD, Yin Mon Myat, MD, Nicholas D'Cunha, MD, Myint Aung Win, MDMBBS, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 5480.

https://doi.org/10.1182/blood-2019-123231

Published: 2019

Journal Articles

Efficacy of Ibrutinib in Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Combined Analysis of Four Phase III Randomized Controlled Trials

Anita Sultan, MD, Chandler Graf, Donald P. Quick, MD, Sriman Swarup, MDMBBS, Jonathan Kopel, BS, Thura Win Htut, MBBS, MRCP, Nimesh Adhikari, MD, Myat Min Han, MD, Yin Mon Myat, MD, Sanjay Awasthi, MD, Lukman Tijani, MD, Nicholas D'Cunha, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 5481.

https://doi.org/10.1182/blood-2019-123233

Published: 2019

Journal Articles

Cellular and Molecular Characterization of Breast Cancer Chemotherapy-Related B Cell Lymphomas

Madeline Rodriguez Valentin, PhD, Darwing Rivas, BSc, Vesna Jurecic, BSc, Alain Diaz, PhD, Richard Riley, PhD, Daniela Frasca, PhD, Roland Jurecic, PhD

Blood (2019) 134 (Supplement_1): 5241.

https://doi.org/10.1182/blood-2019-127252

Published: 2019

Journal Articles

Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Retrospective, Single-Institution Analysis Based on Risk Features and Debulking Strategy with Anti-CD20 Monoclonal Antibody

Ariel F Grajales-Cruz, MD, Julio Chavez, Virginia Olivia Volpe, MD, Jose Sandoval-Sus, MD, Bijal Shah, MD, Celeste Bello, MD, Lubomir Sokol, MD PhD, Shanel Fisher, Rajesh R Nair, PhD, Yun Seongseok, MD, Hayder Saeed, MD, Leidy Isenalumhe, MD, Elyce P. Turba, MSN, RN, Lisa Nodzon, PhD ARNP, AOCNP, Javier Pinilla Ibarz, MD PhD

Blood (2019) 134 (Supplement_1): 5484.

https://doi.org/10.1182/blood-2019-129260

Published: 2019

Journal Articles

ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma

Andrew D. Zelenetz, MD PhD, Pier Luigi Luigi Zinzani, MD, Henry Chan, MBChB, Christian Buske, MD PhD, Vincent Ribrag, David Cunningham, MD FRCP, FMedSci, Wojciech Jurczak, Pau Abrisqueta, MD PhD, Joanne Li, Igor Gorbatchevsky, MD, Jennifer R. Brown, MD PhD

Blood (2019) 134 (Supplement_1): 5244.

https://doi.org/10.1182/blood-2019-124326

Published: 2019

Journal Articles

Clinical Outcomes of Obinutuzumab Therapy across Non-Hodgkin Lymphoma Subtypes

Mitchell E. Hughes, PharmD, Esin C. Namoglu, B.S., Connie Suen, PharmD, Stephen J Schuster, MD, Jakub Svoboda, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Kyle Robinson, MD, Elise A. Chong, MD, Joanna M Rhodes, MD, Emily C. Ayers, MD, Alison W. Loren, MD MSCE, Edward A. Stadtmauer, MD FACP, Sunita Dwivedy Nasta, MD

Blood (2019) 134 (Supplement_1): 5247.

https://doi.org/10.1182/blood-2019-128148

Published: 2019

Journal Articles

Risk of Serious Adverse Events, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Treated with Idelalisib

Jonathan Kopel, BS, Sriman Swarup, MDMBBS, Anita Sultan, MD, Lukman Tijani, MD, Ei Moe Phyu, MD, Myint Aung Win, MDMBBS, Thura Win Htut, MBBS, MRCP, Ye Aung, Akshar Dash, Myat Min Han, MD, Yin Mon Myat, MD, Donald P. Quick, MD, Nicholas D'Cunha, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 5489.

https://doi.org/10.1182/blood-2019-123179

Published: 2019

Journal Articles

Association of Insurance Status and Marital Status with Outcomes of Patients with Chronic Lymphocytic Leukemia: A Population-Based Study

Yi Miao, MD PhD, Wei Xu, MD PhD, Lei Fan, MD PhD, Jianyong Li, MD

Blood (2019) 134 (Supplement_1): 5459.

https://doi.org/10.1182/blood-2019-127756

Published: 2019

Journal Articles

Incidence of Serious Adverse Events, Pneumonitis, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Treated with Phosphatidylinositol 3-Kinase (PI3K) Inhibitors

Sriman Swarup, MDMBBS, Donald P. Quick, MD, Anita Sultan, MD, Myint Aung Win, MDMBBS, Ei Moe Phyu, MD, Thura Win Htut, MBBS, MRCP, Sariya Wongsaengsak, MD, Myet Mon Zin, MD, Myat Min Han, MD, Yin Mon Myat, MD, Sanjay Awasthi, MD, Lukman Tijani, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 798.

https://doi.org/10.1182/blood-2019-123177

Published: 2019

Journal Articles

First Line Treatment with Venetoclax and Ibrutinib Induction Followed By Obinutuzumab Intensification Exclusively in CLL/SLL Patients Not in Complete Remission and/or with Detectable Bone Marrow Minimal Residual Disease (NEXT STEP trial)

Sabina Kersting, MD PhD, Mark-David Levin, MD PhD, Carsten Utoft Niemann, MD PhD, Yvette Norden, PhD, Arnon P. Kater, MD PhD

Blood (2019) 134 (Supplement_1): 1753.

https://doi.org/10.1182/blood-2019-124550

Published: 2019

Journal Articles

A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL

Jennifer L. Crombie, MD, Svitlana Tyekucheva, PhD, Alexandra Savell, BS, Karen Francoeur, RN, Mark Choiniere, BA, Josie Montegaard, NP, Jacob D. Soumerai, MD, Jon E. Arnason, MD, David C. Fisher, MD, Jennifer R. Brown, MD PhD, Matthew S. Davids, MD

Blood (2019) 134 (Supplement_1): 1763.

https://doi.org/10.1182/blood-2019-127343

Published: 2019

Journal Articles

Clinical Utility of Chromosomal Microarray in Establishing Clonality and High Risk Features in Patients with Richter Transformation

James Kalmuk, MD, Daynna Wolff, PhD FACMG, Cynthia Schandl, MD PhD, Sandra Mazzoni, BS,DO,MT(ASCP), Iya Znoyko, PhD, Zane Chiad, MD, Lindsey Hendrickson, DNP, APRN, FNP-C, Irl Brian Greenwell, MD, Brian T. Hess, MD

Blood (2019) 134 (Supplement_1): 1736.

https://doi.org/10.1182/blood-2019-124514

Published: 2019

Journal Articles

Shared Decision Making in Cancer Treatment: Findings from a Large Survey of Lymphoma (LYM) Patients and Survivors

Kendall H Sullivan, PharmD, Michael Toscani, PharmD, Tayla Poretta, PharmD, Ciera Patzke, PharmD, BCOP, Thushara Korattyil, PharmD, Denalee O'Malley, PhD MSW, Victor Gonzalez, MA, MS, Joseph Barone, PharmD, Andrew M. Evens, DO,MSc

Blood (2019) 134 (Supplement_1): 2134.

https://doi.org/10.1182/blood-2019-123459

Published: 2019

Journal Articles

Updated Meta-Analysis to Evaluate the Incidence of Atrial Fibrillation and Major Bleeding in Patients with Hematologic Malignancies Treated with Ibrutinib

Sriman Swarup, MDMBBS, Anita Sultan, MD, Lukman Tijani, MD, Thura Win Htut, MBBS, MRCP, Nicholas D'Cunha, MD, Sariya Wongsaengsak, MD, Donald P. Quick, MD, Khaing Khaing Htwe, Pwint Phyu Hlaing, MD, Myat Min Han, MD, Yin Mon Myat, MD, Akshar Dash, Fred Hardwicke, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 2200.

https://doi.org/10.1182/blood-2019-123261

Published: 2019

NARROW

Simultaneous bone marrow involvement by CLL/SLL and LEF1/cyclin D1-positive metastatic melanoma

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

Combining Gene Expression Profiling and Artificial Intelligence to Diagnose B-Cell Non-Hodgkin Lymphoma

Efficacy and Safety of Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia

Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Combined Analysis of Three Phase III Randomized Controlled Trials

Decreased Thrombin Generation Potential in Lymphoma Patients Is Associated with Increased D-Dimer, CRP, Vwf and TNF-α. Interrelationship between Thrombogenesis and Inflammation

Efficacy of Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Efficacy of Ibrutinib in Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Combined Analysis of Four Phase III Randomized Controlled Trials

Cellular and Molecular Characterization of Breast Cancer Chemotherapy-Related B Cell Lymphomas

Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Retrospective, Single-Institution Analysis Based on Risk Features and Debulking Strategy with Anti-CD20 Monoclonal Antibody

ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma

Clinical Outcomes of Obinutuzumab Therapy across Non-Hodgkin Lymphoma Subtypes

Risk of Serious Adverse Events, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Treated with Idelalisib

Association of Insurance Status and Marital Status with Outcomes of Patients with Chronic Lymphocytic Leukemia: A Population-Based Study

Incidence of Serious Adverse Events, Pneumonitis, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Treated with Phosphatidylinositol 3-Kinase (PI3K) Inhibitors

First Line Treatment with Venetoclax and Ibrutinib Induction Followed By Obinutuzumab Intensification Exclusively in CLL/SLL Patients Not in Complete Remission and/or with Detectable Bone Marrow Minimal Residual Disease (NEXT STEP trial)

A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL

Clinical Utility of Chromosomal Microarray in Establishing Clonality and High Risk Features in Patients with Richter Transformation

Shared Decision Making in Cancer Treatment: Findings from a Large Survey of Lymphoma (LYM) Patients and Survivors

Updated Meta-Analysis to Evaluate the Incidence of Atrial Fibrillation and Major Bleeding in Patients with Hematologic Malignancies Treated with Ibrutinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only